PD-008 Adding ramucirumab to second-line irinotecan, 5-fluorouracil and folinic acid (FOLFIRI) treatment for metastatic colorectal carcinoma (mCRC): resource utilization data from RAISE, a global, randomized, double-blind, multicenter phase 3 study

Documenti analoghi

• Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression(†)
  di: Obermannová, R., et al.
  Pubblicazione: (2016)
• Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)
  di: Souglakos, J, et al.
  Pubblicazione: (2012)
• Safety and Effectiveness of Aflibercept + Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) for the Treatment of Patients with Metastatic Colorectal Cancer (mCRC) in Current Clinical Practice: OZONE Study
  di: Chau, Ian, et al.
  Pubblicazione: (2020)
• PD-029 Baseline carcinoembryonic antigen (CEA) as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma (mCRC) phase 3 trial
  di: Yoshino, T., et al.
  Pubblicazione: (2016)
• Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer
  di: Höhler Thomas, et al.
  Pubblicazione: (2004-07-01)